BioXcel Therapeutics, Inc. (BTAI)
OTC: BTAI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2017
Who owns BioXcel Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Integrated Core Strategies (US) LLC holds 8.4% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Feb 9, 2026 says.
Directors and officers
12
report now, of 17 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Integrated Core Strategies (US) LLC
SCHEDULE 13G/A · filed Feb 9, 2026 · Common Stock, par value $0.001 per share · 5.2% in Oct 1, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 · reported falling below 5%, from 7.05% in May 15, 2026
Oaktree Capital Holdings, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.2% in Dec 18, 2024
Qatar Investment Authority
SCHEDULE 13G/A · filed Mar 30, 2026 · Common Stock, par value $0.001 · reported falling below 5%, from 5.2% in Dec 18, 2024
What BTAI reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 27, 2026.
Insider tradesForm 4
4sales
0purchases
4sales on a scheduled plan
4people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 35 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President | 1 | $0 | 1 | 0 | $0 |
| Rodriguez Javier | Chief Legal Officer, Senior Vice President and Corporate Secretary | 1 | $0 | 1 | 0 | $0 |
| Steinhart Richard I | Chief Financial Officer | 1 | $0 | 1 | 0 | $0 |
| Yocca Frank | Chief Scientific Officer | 1 | $0 | 1 | 0 | $0 |